EUVIMEDEUVIMED entdecken
Crossref

Discovery of 1,3,4-Oxadiazole Derivatives as Broad-Spectrum Antiparasitic Agents

Alexandra Ioana Corfu iD, Nuno Santarem, Sara Luelmo, Gaia Mazza, Alessandro Greco, Alessandra Altomare, Giulio Ferrario, Giulia Nasta, Oliver Keminer, Giancarlo Aldini, Lucia Tamborini iD, Nicoletta Basilico und 5 weitere

ACS Infectious Diseases · 14.06.2024 · 10 (6) · 2222-2238

DOI: 10.1021/acsinfecdis.4c00181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 08.05.2024. Verfasst von Alexandra Ioana Corfu und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, 20133 Milan, Italy. Hauptthemen laut MEDLINE: Oxadiazoles, Trypanosoma brucei brucei, Drug Discovery. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Università degli Studi di Milano, European Social Fund Plus, L'Oreal USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vector-borne parasitic diseases (VBPDs) pose a significant threat to public health on a global scale. Collectively, Human African Trypanosomiasis (HAT), Leishmaniasis, and Malaria threaten millions of people, particularly in developing countries. Climate change might alter the transmission and spread of VBPDs, leading to a global burden of these diseases. Thus, novel agents are urgently needed to expand therapeutic options and limit the spread of drug-resistant parasites. Herein, we report the development of broad-spectrum antiparasitic agents by screening a known library of antileishmanial and antimalarial compounds toward Trypanosoma brucei (T. brucei) and identifying a 1,3,4-oxadiazole derivative (19) as anti-T. brucei hit with predicted blood-brain barrier permeability. Subsequently, extensive structure-activity-relationship studies around the lipophilic tail of 19 led to a potent antitrypanosomal and antimalarial compound (27), with moderate potency also toward Leishmania infantum (L. infantum) and Leishmania tropica. In addition, we discovered a pan-active antiparasitic molecule (24), showing low-micromolar IC50s toward T. brucei and Leishmania spp. promastigotes and amastigotes, and nanomolar IC50 against Plasmodium falciparum, together with high selectivity for the parasites over mammalian cells (THP-1). Early ADME-toxicity assays were used to assess the safety profile of the compounds. Overall, we characterized 24 and 27, bearing the 1,3,4-oxadiazole privileged scaffold, as broad-spectrum low-toxicity agents for the treatment of VBPDs. An alkyne-substituted chemical probe (30) was synthesized and will be utilized in proteomics experiments aimed at deconvoluting the mechanism of action in the T. brucei parasite.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OxadiazolesTrypanosoma brucei bruceiDrug DiscoveryHumansStructure-Activity RelationshipAntiparasitic AgentsAntimalarialsLeishmania infantumAnimalsAntiprotozoal Agents

Stichwörter der Autor:innen

1,3,4-oxadiazoleADME-Toxbroad-spectrum moleculeshuman African trypanosomiasisleishmaniasismalariavector-borne parasitic diseases

Substanzen

Oxadiazoles1,3,4-oxadiazoleAntiparasitic AgentsAntimalarialsAntiprotozoal Agents

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, University of Milan, Via Mangiagalli 25, 20133 Milan, Italy.
  • Institute for Research and Innovation in Health (i3S), University of Porto, 4200-135 Porto, Portugal.
  • Department of Biological Sciences, Faculty of Pharmacy, University of Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal.
  • Department of Biomedical, Surgical and Dental Sciences, University of Milan, Via Pascal 36, 20133 Milan, Italy.
  • Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy.
  • Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Schnackenburgallee 114, 22525 Hamburg, Germany.

ORCID-Profile: Alexandra Ioana Corfu, Lucia Tamborini, Sheraz Gul, Paola Conti, Chiara Borsari

Förderung

  • Università degli Studi di Milano
  • European Social Fund Plus
  • L'Oreal USA
  • Fundação para a Ciência e a Tecnologia

Zitieren

APA

Corfu, A. I., Santarem, N., Luelmo, S., Mazza, G., Greco, A., Altomare, A., Ferrario, G., Nasta, G., Keminer, O., Aldini, G., Tamborini, L., Basilico, N., Parapini, S., Gul, S., Cordeiro-da-Silva, A., Conti, P., & Borsari, C. (2024). Discovery of 1,3,4-Oxadiazole Derivatives as Broad-Spectrum Antiparasitic Agents. ACS Infectious Diseases, 10(6), 2222-2238. https://doi.org/10.1021/acsinfecdis.4c00181

Vancouver

Corfu AI, Santarem N, Luelmo S, Mazza G, Greco A, Altomare A, et al. Discovery of 1,3,4-Oxadiazole Derivatives as Broad-Spectrum Antiparasitic Agents. ACS Infectious Diseases. 2024;10(6):2222-2238. doi:10.1021/acsinfecdis.4c00181

BibTeX
@article{Corfu2024,
  author = {Corfu, Alexandra Ioana and Santarem, Nuno and Luelmo, Sara and Mazza, Gaia and Greco, Alessandro and Altomare, Alessandra and Ferrario, Giulio and Nasta, Giulia and Keminer, Oliver and Aldini, Giancarlo and Tamborini, Lucia and Basilico, Nicoletta and Parapini, Silvia and Gul, Sheraz and Cordeiro-da-Silva, Anabela and Conti, Paola and Borsari, Chiara},
  title = {Discovery of 1,3,4-Oxadiazole Derivatives as Broad-Spectrum Antiparasitic Agents},
  journal = {ACS Infectious Diseases},
  year = {2024},
  volume = {10},
  number = {6},
  pages = {2222--2238},
  doi = {10.1021/acsinfecdis.4c00181}
}
Kostenlos starten →